What non‑pharmacologic first‑line management strategies are recommended for a reproductive‑age woman with adenomyosis who wishes to avoid medications?

Non-Pharmacologic Management of Adenomyosis

For a reproductive-age woman with adenomyosis wishing to avoid medications, there are essentially no effective non-pharmacologic first-line options—the evidence overwhelmingly supports that medical management (hormonal therapies) is first-line, with procedural interventions reserved for refractory cases or specific clinical scenarios. 1, 2

The Reality of Non-Pharmacologic Options

The available guidelines and evidence do not support any truly non-pharmacologic first-line management for adenomyosis. Here's what exists:

Procedural/Interventional Options (Not First-Line)

Uterine Artery Embolization (UAE) is the primary non-pharmacologic option, but it is recommended only after conservative medical measures have failed and when uterus preservation is desired 1, 2:

• UAE provides short-term symptom improvement in 94% of patients and long-term improvement in 85% 1, 2
• Only 7-18% of patients require subsequent hysterectomy for persistent symptoms 1, 2
• Quality of life and symptom scores improve for up to 7 years post-procedure 2
• Critical caveat: Comprehensive data on fertility and pregnancy outcomes after UAE is lacking, and patients must be counseled accordingly 1
• UAE may be less effective when adenomyosis is the predominant condition compared to when fibroids predominate 1

Other Minimally Invasive Procedures (Limited Evidence)

Recent research describes additional procedural options, though these lack guideline-level recommendations 3:

• Radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and percutaneous microwave ablation (PMWA) have shown effectiveness in reducing abnormal uterine bleeding and dysmenorrhea 3
• These interventions are associated with decreased uterine volume and low rates of symptom recurrence 3
• Major limitation: Access to ablative therapies in the USA is limited and primarily off-label due to lack of FDA approval 3
• More data are needed to assess safety and utility in those desiring future fertility 3

Conservative Surgery (High-Risk Option)

Adenomyomectomy (surgical excision of adenomyotic tissue) is an option for fertility preservation, but comes with significant concerns 4:

• Requires highly experienced surgeons 4
• Poses considerable risk of uterine rupture during subsequent pregnancies 4
• Surgical recurrence is common, with up to 44% of women experiencing symptom recurrence within one year 1, 5
• Important pitfall: Myomectomy alone does not address adenomyosis and is ineffective for this condition 5

Definitive Surgery (Not Conservative)

Hysterectomy is the only definitive cure but obviously not appropriate for women wishing to preserve fertility 2, 5:

• The least invasive route should be chosen—vaginal or laparoscopic approaches preferred over abdominal 1, 5
• Even with ovarian conservation, hysterectomy carries risks including cardiovascular disease, mood disorders, osteoporosis, and potentially increased dementia risk 5

Why Medical Management Cannot Be Avoided

The fundamental problem is that no medical therapy has been proven to eradicate adenomyosis lesions—all treatments provide only temporary symptom relief 1:

• Adenomyosis is an estrogen-dependent disease requiring hormonal suppression for symptom control 6, 4
• Without hormonal intervention, the disease persists and symptoms continue 7, 4
• There is no evidence that medical treatment affects future fertility negatively 1

Clinical Algorithm for This Patient

Given the evidence, here is the realistic approach:

1. Counsel the patient that truly effective non-pharmacologic first-line options do not exist for adenomyosis management 1, 2

2. If symptoms are mild and tolerable, expectant management with monitoring may be reasonable, though this is not "treatment" 2

3. If symptoms require intervention and the patient absolutely refuses medications:

   • Consider UAE if fertility is not an immediate concern and after thorough counseling about unknown fertility effects 1, 2
   • Refer to specialized centers for investigational ablative therapies (RFA, HIFU, PMWA) if available 3
   • Consider adenomyomectomy only at highly experienced centers if fertility preservation is critical, with extensive counseling about uterine rupture risk 4

4. Strongly reconsider medical management: The levonorgestrel-releasing IUD provides significant improvement in pain and bleeding and is the evidence-based first-line approach 1, 2, 5

Key Pitfalls to Avoid

• Do not perform endometrial ablation in the presence of adenomyosis—it has high failure rates 5
• Do not assume procedural interventions are first-line—they are reserved for refractory cases 1, 2
• Do not offer myomectomy alone for adenomyosis treatment—it is ineffective 5
• Ensure endometrial biopsy has been performed to rule out endometrial cancer or hyperplasia, especially in perimenopausal women 5